Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages

  Kumthip, K ^a   Pantip, C ^a   Chusri, P ^a   Thongsawat, S ^a   O'Brien, A ^a   Nelson, K E ^b   Maneekarn, Niwat ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Core; Hepatitis C virus; Mutations; NS5A; Pegylated interferon; Ribavirin

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79952652957     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01379.x     Document Type: Article

References (34)

1. Weigand K, Stremmel W, Encke J. Treatment of hepatitis C virus infection. World J Gastroenterol 2007; 13: 1897-1905. (Pubitemid 46758855)
2. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003; 59: 1-11.
3. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
4. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999. (Pubitemid 38670134)
5. Gale MJ, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 30: 217-227. (Pubitemid 27211852)
6. Gale MJ, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 1998; 10: 157-162. (Pubitemid 28399034)
7. Lin W, Kim SS, Yeung E et al. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 2006; 80: 9226-9235. (Pubitemid 44359995)
8. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
9. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81. (Pubitemid 26017933)
10. Chayama K, Tsubota A, Kobayashi M et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 5: 745-749. (Pubitemid 27106464)
11. Watanabe H, Enomoto N, Nagayama K et al. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 2001; 183: 1195-1203. (Pubitemid 32281558)
12. Murayama M, Katano Y, Nakano I et al. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B. J Med Virol 2007; 79: 35-40. (Pubitemid 44902051)
13. Nousbaum J, Polyak SJ, Ray SC et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000; 74: 9028-9038.
14. Veillon P, Payan C, Gaudy C, Goudeau A, Lunel F. Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin. Pathol Biol 2004; 52: 505-510. (Pubitemid 39504829)
15. El-Shamy A, Sasayama M, Nagano-Fujii M et al. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol 2007; 51: 471-482. (Pubitemid 46641684)
16. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48: 38-47. (Pubitemid 351975529)
17. Akuta N, Suzuki F, Sezaki H et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380. (Pubitemid 41003622)
18. Akuta N, Suzuki F, Sezaki H et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90. (Pubitemid 41783847)
19. Theamboonlers A, Chinchai T, Bedi K, Jantarasamee P, Sripontong M, Poovorawan Y. Molecular characterization of hepatitis C virus (HCV) core region in HCV- infected Thai blood donors. Acta Virol 2002; 46: 169-173. (Pubitemid 35477128)
20. Hofmann WP, Zeuzem S, Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 2005; 32: 86-91. (Pubitemid 40093958)
21. Chung RT, Tai AW. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 2009; 50: 412-420.
22. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617. (Pubitemid 41007847)
23. Hayashi K, Katano Y, Ishigami M et al. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated interferon- alpha 2b and ribavirin combination therapy. J Viral Hepat 2010; doi:10.1111/j.1365-2893.2010.01305.x.
24. Chen TM, Huang PT, Wen CF, Tung JN, Chow KC, Chen YP. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy. J Viral Hepat 2010; doi:10.1111/j.1365-2893.2010.01287.x.
25. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25: 740-744. (Pubitemid 27106463)
26. Duverlie G, Khorsi H, Castelain S et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998; 79: 1373-1381. (Pubitemid 28258445)
27. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol 1999; 58: 353-358. (Pubitemid 29326048)
28. Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477. (Pubitemid 44142464)
29. Howell CD, Dowling TC, Paul M et al. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2008; 6: 575-583.
30. Pascu M, Martus P, Höhne M et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004; 53: 1345-1351. (Pubitemid 39120125)
31. Castelain S, Khorsi H, Roussel J et al. Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivity. J Infect Dis 2002; 185: 573-583. (Pubitemid 34171461)
32. Okanoue T, Itoh Y, Hashimoto H et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009; 44: 952-963.
33. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 2004; 279: 48576-48587. (Pubitemid 39625732)
34. Moradpour D, Brass V, Penin F. Function follows form: the structure of the N-terminal domain of HCV NS5A. Hepatology 2005; 42: 732-735. (Pubitemid 41233668)